RxDoctor Payments Data

Michael Allen, MD

Internal Medicine · Evansville, INNPI 1366429714

Payments from drug & device makers

$280in general payments, 2019–2025

Across 17 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$75
  • Amgen$42
  • Novo Nordisk$30
  • GSK$23
  • Alfasigma USA, Inc.$14
  • Teva Pharmaceuticals USA, Inc.$13
  • plus $84 from 7 others

What the payments were for

  • Food & beverage$20573%
  • Education$7527%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$280 in reported general payments places this provider in the 55th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$149,726
Medicare patients
533
Services billed
1,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$72,697
MounjaroTirzepatide57$58,563
FarxigaDapagliflozin Propanediol44$49,725
JardianceEmpagliflozin45$48,086
JanuviaSitagliptin Phosphate49$47,042
BiktarvyBictegrav/Emtricit/Tenofov Ala12$47,009
Tresiba Flextouch U-100Insulin Degludec56$42,564
LinzessLinaclotide55$37,574
OzempicSemaglutide22$25,046
XareltoRivaroxaban26$24,285
TradjentaLinagliptin14$21,677
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,153
Tresiba Flextouch U-200Insulin Degludec17$20,315
Breo ElliptaFluticasone/Vilanterol23$17,492
MyrbetriqMirabegron13$12,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$12$78,70970 claims
PfizerEliquis$11$72,69763 claims
Lilly USA, LLCMounjaro$11$58,56357 claims
AbbVieLinzess, Synthroid$12$46,786199 claims
GSKTrelegy Ellipta, Breo Ellipta$23$38,64555 claims
Novo NordiskOzempic$30$25,04622 claims
Johnson & JohnsonXarelto$13$24,28526 claims
Astellas Pharma US IncMyrbetriq$75$12,47813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Evansville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →